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Abstract
Immune mechanisms underlying the pathophysiology of idiopathic nephrotic syndrome, the most frequent glomerular
disease in children, are believed to involve a systemic disorder of T cell function and cell mediated immunity. How these
perturbations take place remains unclear. We report here that NFRKB, a member of the chromatin remodeling complex, is
upregulated in MCNS relapse, mainly in CD4+T cells and B cells and undergo post-translational modifications including
sumoylation. We showed that NFRKB was highly expressed in nuclear compartment during the relapse, while it was
restricted to cytoplasm in remission. NFRKB induced the activation of AP1 signaling pathway by upregulating the expression
of c-jun. We showed that NFRKB promotes hypomethylation of genomic DNA, suggesting its implication in regulation of
gene expression by enhancing the binding of transcription factors through chromatin remodeling. These results suggest for
the first time that NFRKB may be involved in the disorders of transcriptional regulation commonly observed in MCNS
relapse.
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Introduction
Idiopathic nephrotic syndrome (INS) is a kidney disease defined
by a massive proteinuria and hypoalbuminaemia. Primary INS
includes two major histological variants: minimal-change nephrot-
ic syndrome (MCNS) and focal segmental glomerulosclerosis
(FSGS), which account for 70% and 20% of INS in children,
respectively and 25% each in adults [1], [2]. Both entities are
considered as non-inflammatory diseases and are characterized by
glomerular epithelial cell injury leading to massive proteinuria.
Although MCNS and FSGS with relapse are considered as
immunologically-mediated diseases, MCNS has rather a benign
course, while the prognosis of FSGS may be more severe,
depending of its sensitivity to steroid and immunosuppressive
drugs.
MCNS is often triggered by immunogenic stimuli such as viral
infections, immunizations or allergens [2–4]. Active disease is
associated with alteration of both humoral immunity and cell-
mediated immunity [4], [5]. The association of MCNS with
primary immunological disorders such as Hodgkin’s lymphoma
[6], leukemia [7] and thymoma [8] support the hypothesis of a
disorder of the immune system. Production of many cytokines is
increased in relapses, suggesting that the disease is associated with
perturbations of the transcriptional machinery [5], [9].
The chromosome DNA is tightly folded in complex with histone
proteins, forming nucleosomes in a chromatin structure. Initiation
of gene transcription is strongly inhibited on such a nucleosomal
template [10]. Gene transcription requires restructuring of
chromatin with nucleosomal unfolding, leading to a more open
access to the DNA. The modifications of chromatin structure and
properties include DNA methylation, histone modifications and
functional miRNA processing. Compelling evidence supports the
interdependence of these epigenetic mechanisms [11].
The INO80 chromatin remodeling complex is a large multi-
subunit ATP-dependent protein complex that regulates the
assembly, disassembly of nucleosomes, facilitating their sliding
along DNA. The function of INO80 complex involves transcrip-
tional regulation, DNA repair and DNA replication [12]. The
human INO80 complex includes several ATPases (Ino80p, Ruv1
Ruv2b), actin-related proteins (ARP) and non-conserved subunits
including the Gli-Kruppel zinc finger transcription factor Yin-
Yang 1 (YY1), the deubiquitylating enzyme Uch37 and nuclear
factor related to kB (NFRKB), which has recently been identified
as member of this complex [13]. Although the ATPases subunits
mediate the ATP-dependent nucleosome remodeling activity, the
precise function of the other subunits remains unclear. Evidence
from microarray experiments revealed that the INO80 complex
contributes to positive or negative regulation of transcription of up
to 20% of genes in yeast [14], [15]. In human cells, the INO80
subunit YY1 recruits the complex and controls transcription of a
large number of genes [16]. Currently, the role of NFRKB as
chromatin remodeling factor remains unknown.
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cloning and differential screening from T cells of patients with
MCNS led us to identify NFRKB among genes of which the
expression is upregulated in relapse [17]. The NFRKB gene is
localized in 11q24-q25 and encodes for 25 exons spanning
29,234 bp. The full-length mRNA contains 5046 bp, which
encodes for a 1324 amino acid-protein with a predicted molecular
weight of 150 kDa. Our knowledge about the function of NFRKB
is very limited so that it is difficult to understand its potential
implication in immune cell disturbances occurring during MCNS
relapse. Thus, we carried out functional studies aiming to
characterize the NFRKB-mediated signaling pathways.
Results
Isolation and characterization of NFRKB
We identified the NFRKB transcript by differential screening of
a cDNA library using subtractive cDNA probes prepared from
lymphocyte mRNAs isolated from the same patient during the
relapse and remission phases [17]. The full-length transcript
contains 5046 nucleotides with a coding sequence of 3972
nucleotides, while the 39- and 59-UTR consist of 201 bp and
950 bp, respectively.
The predicted NFRKB protein contains 1324 amino acids. Its
primary structure consists of several interacting docking sites
including five PKC domains, an Erk domain, a GSK3 kinase
domain, four Src homology 3 (SH3) domains and a bipartite
nuclear signal (http://scansite.mit.edu/cgi-bin/motifscan). Immu-
noblotting of protein lysates from Jurkat cell with anti-NFRKB
antibody detected a protein-doublet, corresponding to two
isoforms (Access numbers P_001137307.1 and NP_006156.2)
with an apparent molecular weight of 145–150 kDa (Fig. 1A), in
close agreement with the molecular mass estimate deduced from
amino acid content (142 kDa). The specificity of the labeling was
checked by the loss of the signal following preincubation of the
antibody with NFRKB peptides (Fig. 1A).
We used commercial Northern-blot (each line containing 2
microgr of polyA RNA) to explore the NFRKB expression in
different tissues, using a radiolabelled cDNA corresponding to
entire coding sequence of NFRKB. The transcript was basically
detected at low levels, except in the colon that exhibited a higher
expression (Fig. 1B).
Expression of NFRKB in patients with steroid sensitive
MCNS
We analyzed the expression of NFRKB transcript in peripheral
blood mononuclear cells (PBMC) from six patients with MCNS in
whom both relapse and remission (free of steroid therapy) samples
were available. The transcript was increased in relapse, as
compared with normal subjects (Fig. 2A). In remission, the
NFRKB level was diminished in some patients but remained above
the values observed in normal subjects. The expression of NFRKB
in active membranous nephropathy (MN) was not significantly
different from normal controls, which suggests that the upregula-
tion of NFRKB is apparently not a consequence of nephrotic
syndrome.
Next, we studied the expression of NFRKB in PBMC protein
lysates from patients with MCNS and normal subjects. Unexpect-
edly, anti-NFRKB antibody recognized a band with an apparent
molecular weight of 220 kDa (Fig. 2B). This signal was abrogated
following preincubation of antibody with the immunogenic
peptides. We next screened several PBMC samples from patients
with MCNS relapse (n=13) or remission (n=9) as well as in
normal subjects (n=12). The relative abundance of NFRKB was
significantly increased in relapsed as compared with remission or
Figure 1. Expression of NFRKB in Jurkat cells. A, Western blot of total lysates using anti-NFRKB reveals a double band at the expected size. The
specificity was attested by the loss of the binding upon preincubation of antibody with synthetic peptides corresponding to positions 543–557 and
1091–1106 within the primary structure of NFRKB. These data are representative of three independent experiments. B, Northern blot analysis of
NFRKB. Multiple tissue-Northern blot (Clontech Laboratories, Inc.) was hybridized with a full-length-probe and exposed to Phosphoimager Storm for
24 h. This experiment was repeated once.
doi:10.1371/journal.pone.0030523.g001
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NFRKB isoforms were increased, while in some others, only one
isoform was selectively increased. The reasons of this variability
are unclear. These data are summarized in Fig. 2D. Confocal
microscopy analysis was performed in PBMC from six patients
with steroid sensitive MCNS, in relapse and remission phases. We
observed that near than 50% of PBMC were positive. NFRKB
was highly expressed in a diffuse fashion in nuclear as well as in the
cytoplasm compartments during the relapse phase, while in
remission, its expression was lower and restricted to cytoplasm
compartment (Fig. 3).
To determine whether NFRKB is expressed by a particular
subpopulation of PBMC, we immunoblotted protein extracts from
cell fractions isolated by immunoselection of PBMC from patients
with relapse. The Fig. 4 shows that NFRKB was mostly
upregulated in CD4+T cells and B cells from relapse, with a
lesser amount produced in monocytes.
The discrepancy between the apparent molecular weight
detected in Jurkat cells and in MCNS patients led us to investigate
whether NFRKB was differentially spliced in the disease. We
performed Northern-blot analysis using total RNA from patients
with relapse. We only visualized a 5.2 kb-transcript, which co-
migrates with the mature NFRKB mRNA detected in jurkat cells
(Fig. 5). These results suggest that patients with MCNS did not
display abnormal spliced NFRKB forms, but that the post-
Figure 2. Differential expression of NFRKB in MCNS. A, RT-PCR analyses in six patients with MCNS during the relapse and remission phase. The
top panel shows the quantification of PCR products, as determined using the Image Quant, version 1.11, analysis software, after normalization against
the corresponding GAPDH mRNA values (&, relapse; %, remission). These data are representative of two independent experiments. B, Western blots
of PBMC protein lysates using anti-NFRKB antibody reveals a larger size of the protein (<220 kDa), compared with the band visualized in jurkat cell
lysates. The specificity was confirmed by the loss of the binding upon preincubation of antibody with specific peptides. These data are representative
of three independent experiments. C, Western blot analysis of NFRKB abundance in PBMC of patients with MCNS relapse or remission and in normal
subjects. These data are representative of three independent experiments. D, The relative abundance of NFRKB was assessed by quantifying the
specific band after normalization with the corresponding actin, using the Image J software. The amount of NFRKB is significantly increased in relapse,
as compared with remission or normal subjects (*p,0.05; ** p,0.01, unpaired t test).
doi:10.1371/journal.pone.0030523.g002
Figure 3. Confocal microscopy analysis of NFRKB staining in
MCNS PBMC. Immunofluorescence of PBMC from relapse and
remission with anti-NFRKB antibody. Note that NFRKB is expressed in
nuclei and cytoplasm compartments during the relapse but it is
restricted to cytoplasm in remission. These data are representative of
three independent experiments.
doi:10.1371/journal.pone.0030523.g003
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bands.
Post-translational modifications of NFRKB include N-
glycosylation and sumoylation
Because the asparagine residues are highly represented in the
predicted structure of NFRKB, we studied the effects of
endoglycosidase-F, an enzyme that cleaves the glycosidic bond
between two N-acetylglucosamine residues. The Fig. 6 (upper
panel) shows mobility electrophoretic of NFRKB incubated in the
absence or in the presence of endoglycosidase-F. The NFRKB
band decreased from 220 kDa to 200 kDa after endoglycosidase-F
treatment, yet higher than the immunoreactive band detected in
jurkat cells. In addition, four high probable putative sites for
sumoylation were identified in NFRKB (VKEE211–215, IKSE351–354;
IKSE382–386 and VKYD663–666). To assess whether the sumoylation
of NFRKB might account for the apparent higher molecular weight,
we performed immunoprecipitation from PBMC protein lysates of
two MCNS relapse samples and eluates were detected either with
anti-sumo-1 or anti-sumo-2/3 antibodies and then reprobed with
anti-NFRKB. As shown in Fig. 6 (lower panel), anti-sumo-2/3
reacted with a major 220 kDa-band, which was specifically
recognized by anti-NFRKB antibody. A minor sumo-2/3 reactive
band was also faintly recognized by anti-NFRKB. By contrast, we
did not detect any signal with anti-sumo-1 antibody, suggesting that
NFRKB did not contain sumo-1.
NFRKB positively regulates AP1 signaling pathway by
upregulating the expression of c-jun
Because NFRKB was highly expressed in nuclear compartment
during the relapse, we sought to determine whether it influences
different signaling pathways. We studied by EMSA experiments
the activation of NF-kB, ISRE, NFAT and AP1 in HEK cells
transfected with NFRKB expression plasmid or empty vector.
Overexpression of NFRKB increased AP1 DNA binding activity
(Fig. 7A), while we did not found any effect on other transcription
factor activities (data not shown). The specificity of the binding was
attested by the loss of the shift when nuclear extracts were
incubated with the mutated probe or in the presence of anti-cjun
antibody. AP-1 activity is induced, among others, by cytokines and
growth factors. In many cell types, including the immune cells,
AP1 activity is composed primarily of Jun and Fos heterodimers
[18]. The induction of AP1 binding activity was associated with an
increased abundance of c-jun in nuclear extracts of HEK cells
transfected with NFRKB, as shown in Fig. 7B. To examine
whether binding to AP1 DNA binding site was functionnaly active,
we performed luciferase assay in HEK cells. The AP1-luc reporter
was transfected into HEK cells with a full-length NFRKB
expression construct or the empty vector. Whereas the luciferase
activity was very lower in the presence of the empty vector,
NFRKB induces AP1 activity in a dose-dependent fashion
(Fig. 7C).
Figure 4. Expression of NFRKB in PBMC subsets. Western blots of protein lysates from PBMC subsets using anti-NFRKB antibody. Note that
NFRKB is predominantly expressed in CD4+ cells and B cells in MCNS relapse. These data are representative of two independent experiments.
doi:10.1371/journal.pone.0030523.g004
Figure 5. Northern blot analysis of NFRKB in MCNS. Northern
blot of PBMC total RNA from four patients with MCNS relapse, was
hybridized with a full-length-probe and exposed to Phosphoimager
Storm for 24 h. This experiment was repeated once.
doi:10.1371/journal.pone.0030523.g005
Figure 6. Post-translational modifications of NFRKB. A, repre-
sentative experiment of N-glycosidase-F traitement. Total protein
lysates were purified from PBMC, treated with the N-glycosidase-F,
then immunoblotted with anti-NFRKB antibody. Note that the band size
is reduced by ,20 kDa. B, Immunoprecipitation of NFRKB from PBMC
protein lysates followed by immunoblotting with anti-sumo-1 or anti-
sumo-2/3. These data are representative of two independent exper-
iments.
doi:10.1371/journal.pone.0030523.g006
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The regulation of gene expression through epigenetic mecha-
nisms such as DNA methylation and chromatin structure
modification plays an important role in the regulation of gene
expression. Because NFRKB belongs to INO80 complex, which is
involved in chromatin remodeling activity, we examined whether
NFRKB may influence DNA accessibility by monitoring genomic
DNA methylation in HEK cells transfected with NFRKB
expression plasmid. As shown in Fig. 8, the percentage of
methylated DNA was decreased in NFRKB-overexpressing
HEK cells (mean6 SD: 74.1463,64) relatively to cells transfected
with empty vector (mean6 SD: 88.2563,74, *p,0.05). This result
suggests that NFRKB promotes hypomethylation of genomic
DNA, which may facilitate gene transcription.
Discussion
MCNS is associated with immune disturbances of which the
molecular mechanisms remain unclear [4], [5]. In this study, we
show that NFRKB is recruited in active MCNS and display
some unexpected features. We provide evidence that: i) the
NFRKB abundance was increased in MCNS CD4+ Tc e l l sa n d
B cells and undergo post-translational modifications including
sumoylation; ii) NFRKB was highly expressed in nuclear
compartment during the relapse, while it was restricted to
cytoplasm in remission; iii) NFRKB induced the activation of
AP1 signaling pathway by upregulating the expression of c-jun;
iv) NFRKB increases hypomethylation of genomic DNA
suggesting its involvement in the regulation of gene expression
through chromatin remodeling, which enhances the binding of
specific transcription factors.
Sumoylation of NFRKB is consistent with its function in
transcriptional regulation. Sumoylation can either enhance or
inhibit the transcription of target genes, although a majority of
studies have identified a functional role of sumoylation in
transcriptional repression [19]. Because NFRKB was highly
sumoylated in MCNS relapse, while the NFRKB protein detected
by Western blotting in HEK cells after transfection was primarily
non sumoylated, we cannot conclude whether NFRKB enhances
or represses transcription in vivo, notably in relapse. Sumoylation
may also regulate the nucleo-cytoplasmic traffic of proteins [20].
Figure 7. NFRKB induces activation of API transcripton factor. A, AP1 DNA-binding activity of 25 microg of nuclear proteins. Nuclear extracts
from NFRKB-transfected HEK cells were incubated with the wild-type AP1 oligonucleotide (Wt AP1) or with mutant-type AP1(Mut AP1)
oligonucleotide. B, Expression of c-fos and c-jun. Immunoblots were performed with 50 microg of proteins. C, HEK cells were transiently co-
transfected with the NFRKB or empty vector (Ev), and AP1-Luc reporter plasmid. The luciferase activity was measured using the ‘‘Dual Luciferase
reporter Assay’’. The data are presented as relative luciferase activity (firefly luciferase/the renilla luciferase). Statistical analyses were carried out on
data from five independent experiments using the one-way Anova (**p,0.015; Kruskal-Wallis test).
doi:10.1371/journal.pone.0030523.g007
Figure 8. NFRKB induces hypomethylation of genomic DNA.
Genomic DNA was prepared from NFRKB-transfected HEK cells or
empty vector and methylation assay was performed as described in
Materials and Methods. Statistical analyses were carried out on data
from five independent experiments using the two-tailed t-test
(*p,0.05; unpaired t-test).
doi:10.1371/journal.pone.0030523.g008
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(IKSE382–386) or into the bipartite nuclear signal (IKSE351–354).
The shuttling of NFRKB between nuclear and cytoplasm
compartments during the MCNS relapse and remission phases
could reflect differential sumoylation.
AP-1 activation occurs in response to a wide range of stimuli
involved in cellular processes, which promote proliferation,
differentiation, survival and apoptosis [21]. AP-1 protein function
is regulated primarily by phosphorylation [21] and by redox
potential [22]. In unstimulated T cells, AP-1 expression is low, but
there is a rapid induction of AP-1 activity after T cell stimulation.
The lack of AP-1 activation correlated with markedly decreased
IL-2 synthesis and anergic T cells exhibit defective AP-1 activity
[23]. AP-1 regulates at least in part a number of cytokines directly
or through a cooperation with other transcription factors.
Although both Th1 and Th2 express AP-1 after activation, higher
levels of c-Fos and c-Jun are found in Th2 cells [24]. B cell
activation, both T cell–dependent and T cell-independent can lead
to AP-1 activation, through recruitment of PKC and/or CD40
pathways [25], [26].
The potential roles of epigenetic alterations in the pathogenesis
of MCNS disease are suspected on the following arguments: 1)
MCNS relapses are frequently triggered by an external or internal
environmental factor including viral infection, toxin, nutriments,
exposition to chemical products and stress [5], [27]. 2) A genetic
defect cannot explain the relapsing-remitting profile of the disease
but epigenetic alterations may occur without a direct change in the
genetic sequence and are potentially reversible. 3) Epigenetic
alterations have been reported in autoimmune disease with
frequent/remission phases such as systemic lupus erythematosus
and rheumatic diseases [28]. 4) Steroid therapy may induce
remission by reversing epigenetic changes [29].
The lymphoid tissues associated with the intestine are exposed
continuously to food antigen and are the largest part of the
immune system. After feeding, T cells are activated locally, in the
intestine-associated lymphoid organs, and in peripheral lymphoid
tissues [30]. Each of these sites contains distinctive populations of
antigen presenting cells and has unique local microenvironments
that may influence the immune response. Inappropriate responses
to food proteins might be responsible for immunopathological
diseases such as food hypersensitivity, inflammatory bowel diseases
and glomerular diseases. The association between celiac disease
and MCNS has been reported [31] and could be more frequent in
children from developing countries. However, the potential
disturbance of mucosal immunity has little explored in MCNS.
Epigenetic mechanisms include DNA methylation, post-trans-
lational modifications of histone tails and changes in miRNA
expression. The INO80 complex functions as an epigenetic
regulator of gene expression via the modifications of chromatin
structure. Chromatin remodeling complexes facilitate the access of
factors that mediate transcription by modulating nucleosome
position and/or composition. Inhibition of DNA methylation by
some drugs, such as hydralazine and procainamide, can cause
lupus-like disease characterized by excessive and inappropriate
transcription. It is now believed that DNA demethylation alters T
cell genes expression and contribute to lupus pathogenesis. A
genetic basis for idiopathic MCNS has not been demontrasted.
Because most patients (,80%) are steroid sensitive, it is unlikely
that a genetic defect, such as identified in steroid resistant
nephrotic syndrome, may explain the pathogenesis of the disease.
On the other hand, the upregulation of NFRKB in MCNS
suggests that epigenetic mechanisms may be involved in immune
disturbances. A wide variety of immunological abnormalities in
MCNS, including observations in vivo and in vitro, affecting both
humoral immunity and cell-mediated immunity has been reported
[4]. The cytokine production in MCNS is complex and includes T
helper 1 (interferon gamma) and T helper 2 (IL13) suggesting a
disorder of transcriptional regulation [4]. A more salient finding in
patients with MCNS is the presence of hypogammaglobulinemia,
which cannot be explained by the urinary loss alone, because only
some IgG fractions (IgG1 and IgG2) seem depressed [4]. The
mechanism of hypogammaglobulinemia is unclear.
MCNS relapses often occur following a rapid contact with a
variety of antigens present in the environment. How the
environment modifies the immune system through epigenetic
mechanisms to cause relapse, remains to be clarified.
Materials and Methods
Patients
The cohort of adult patients analyzed in this study is from our
clinical department. All adult patients with MCNS relapse had
proteinuria above 3 g/24 h and severe hypo-albuminemia at the
time of blood sampling, which was performed before the
beginning of steroid treatment. The diagnosis of kidney disease
was confirmed by renal biopsy. MCNS and MN were clinically
classified as idiopathic in all cases. All patients with MCNS
investigated in this work were steroid sensitive. The demographic,
clinical and biological characteristics of patients are summarized in
Table 1.
Identification of NFRKB
The transcript NFRKB (Accession number: NM_001143835)
has been isolated by subtractive and differential screening of a
cDNA library constructed from peripheral T lymphocytes of
patient with MCNS relapse [17].
Northern Blot
Human multiple-tissue Northern blot (CLONTECH Labora-
tories, Inc.) was hybridized with a cDNA probe corresponding to
the full-length coding sequence. Hybridization and blot processing
were performed as described previously [17].
Purification of PBMC and cell Subsets
Human PBMC were purified through a Ficoll/Hypaque density
gradient (Eurobio, France). The subpopulations of T lymphocytes,
B lymphocytes and monocytes were isolated by immunomagnetic
selection, using a cocktail of hapten conjugated antibody specific of
each corresponding subset (Miltenyi Biotech, Auburn, CA).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared from the PBMC using an RNeasy kit
(Qiagen, Chatsworth, CA, USA). One microg of RNA was reverse
transcribed in the presence of Oligo(dT)12–18 primers, using a
SuperScript
TM First-Strand Synthesis System (Invitrogen, CA).
Samples (2 microl of the RT reaction mixture, corresponding to
50 ng of total RNA) were amplified in a 25 microl reaction
mixture containing 0.2 mM of each NFRKB primer (Table 2) and
0.5 microl of DyNAzyme
TM EXT DNA polymerase (Finnzyme,
Finland). PCR reaction was performed on a GeneAmp 2700
(Applied Biosystem, CA, USA), using the following programs: an
initial denaturation step at 94uC for 3 min, following by 25 cycles
(94uC for 15 sec, 60uC for 30 sec, and 68uC for 2 min), and by a
final extension at 68uC for 10 min. The reaction product was
normalized to the amount of GAPDH product amplified in
parallel, using the appropriate primers (Table 2). The PCR
products were separated on a 1.5% agarose gel, and the intensity
Nuclear Factor-Related Kappa B and MCNS
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Confocal microscopy analyses
Immunostaining of PBMC or cell subpopulations was per-
formed as previously described [9].
Plasmid constructs, cell culture, transient transfections
and luciferase assays
Total RNA was isolated using a Rneasy kit (Qiagen, Chats-
worth, CA). The NFRKB coding sequences was amplified by RT-
PCR using the primers that are suitable for cDNA constructs in
the gateway system (Invitrogen, Inc, CA). The NFRKB mRNA
was prepared from patients with MCNS. Reverse transcription
was performed with Superscript II (Invitrogen, Inc, CA) and PCR
amplification with DyNazyme EXT DNA polymerase (Finnzyme,
Finland) using the following conditions: an initial denaturation step
at 94uC for 2 min, following by 35 cycles (94uC for 15 sec, 64uC
for 30 sec, and 72uC for 5 min), and by a final extension at 72uC
for 10 min. The cDNA product was inserted in the pDonor
plasmid. The quality of cDNA was checked by sequencing. The
full-length NFRKB was transferred into pDest40 by recombina-
tion, using the LR recombinase (Invitrogen, Inc, CA).
Jurkat cells were cultured at 0.5610
6 cells/ml in complete
RPMI medium containing 10% fetal calf serum (FCS), 50 microg/
ml Penicillin, 100 microg/ml Streptomycine and 2 mM Gluta-
mine (Invitogen, France). Human embryonic kidney (HEK) cells
were obtained from the American type Culture Collection. The
cells were maintained in complete DMEM medium and were
transiently transfected with one microg DNA per 10
6 cells using
the nanofectine method according the instructions provided by the
manufacturer (PAA, Austria). The cells were allowed to recover for
24 hours, washed three times in cold PBS and processed for
analysis. To minimize variations in transfection efficiency, the
same cell passage number per cell line was used for all
transfections. The AP-1-luc (Promega, France) vector contains
the firefly luciferase gene under the control of AP-1 enhancer
element. A phRL-null vector (Promega, France), containing a
renilla luciferase gene was used as an internal control for
transfection and luciferase assays.
Immunoprecipitations and Western blot analyses
Primary antibodies used in this study included, anti-sumo-1 (sc-
5308) anti-sumo-2/3 (sc-32873), anti-c-fos (sc-7202), antic-jun (sc-
1694) anti-lamin B (sc-6216) (Santa Cruz, Biotechnology, Inc, CA)
and anti-V5 (Invitrogen, Inc, CA). We generate a rabbit polyclonal
antibody raised against two synthetic peptides corresponding to
Table 1. Demographic, clinical and biological characteristics of patients and normal subjects.
Adults with MCNS
a Adults with MN
a Normal Adults
Number of patients 13 4 12
Age (years)
b 25 (18–39) 30 (25–49) 28 (25–32)
Gender (male/female) 8/5 3/1 7/5
Proteinuria (g/day) 8 (6–25) 5 (3,5–8) negative
Albuminemia (normal 39,5–49 g/L) 14 (8–23) 19 (14–28) NT
d
Plasma creatinine (micromol/l) 95 (75–135) 90 (80–120) NT
Steroid therapy
c Relapse: none
Remission: none
none none
aDiagnosis was established by renal biopsy.
bThe data are presented as mean and extremes values are in parentheses.
cAt the time of blood sampling.
dNT: not tested.
doi:10.1371/journal.pone.0030523.t001
Table 2. Sequence of primers and PCR conditions.
Primers Sequence
Accession
number
Expected
size
Ann
Temp
(6C)
PCR
cycles
Human NFRKB
Full length
Forward
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCAT
GTCTTTGTCCAGAGTACCTGTGGA
Reverse
GGGGACCACTTTGTACAAGAAAGCTGGGTC
CTATTGTTGCTCAGGTGCCTGTTTAGGAGACG
NM_006165 3972 64 40
PCR primers NFRKB
Forward: CTCTGGAACTTGGTCCGTGTGGAGAT
Reverse: CAGGACTAGGAGAACGTGCTGGAGAGC
657 60 32
GAPDH
Forward: ACCACAGTCCATGCCATCAC
Reverse: TCCACCACCCTGTTGCTGTA
NM_004048 374 58 25
The underlined sequences correspond to attB-sites used to incorporate the PCR product into the gateway plasmids.
doi:10.1371/journal.pone.0030523.t002
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of NFRKB, respectively.
Cell protein extracts from cell lines (Jurkat or HEK 293) were
prepared in lysis buffer containing 150 mM NaCl, 10 mM Tris
HCl pH 7.5, 2 mM DTT, 10% glycerol, 1 mM EDTA, 1%
NP40, 1 mM protease inhibitors, 1 mM Na fluoride and 1 mM
sodium orthovanadate). For immunoprecipitation, cell lysates
containing equal amount of protein were precleared with protein
G-sepharose (GE Helthcare Bio-science AB, Upssala, Sweden) for
1 h at 4uC. The beads were presaturated with 5% BSA for 4 h
before use. After preclearing, protein lysates were incubated with
the appropriate antibody for 2 h at 4uC, then 50 microl of protein
G-sepharose beads were added and the incubation was continued
overnight at 4uC. The beads were washed six times with the lysis
buffer B containing 0,1% NP40 and bound proteins were resolved
by 10% SDS-PAGE, transferred on nitrocellulose membrane and
processed for immunoblotting. For controls of immunoprecipita-
tions, the non-immune rabbit or mouse IgG (Alpha Diagnostics
Intl. Inc., San Antonio, USA) were used instead of primary
antibody.
Endoglycosidase treatment
Treatment of PBMC total lysates with recombinant N-
glycosidase-F (0.4 unit/ml, Roche Diagnostic, France) was carried
out at 22uC for 18 h in 100 mM-sodium phosphate, pH 6.0,
containing 75 mM beta-mercaptoethanol, 50 mM-EDTA, 0.5%
(w/v) Triton X-100, 0.05% (w/v) SDS. The enzymatic digestion
was terminated by addition of equal volume of Laemmli buffer.
The samples were then migrated in SDS/polyacrylamide-gel,
transferred in nitrocellulose membranes and immunoblotted with
anti-NFRKB antibody.
Electromobility Shift Assays
Cytosolic and nuclear fractions were prepared essentially as
described previously [32]. Protein concentrations were assayed
using the Bio-Rad dye reagent (Bio-Rad, Richmond, CA),
following the instructions provided by the manufacturer. The
double-stranded oligonucleotide probes (100 ng), with the consen-
sus and mutant NF-kB (sc-2505, sc-2511), GAS/ISRE (sc-2537,
sc-2538), NFATc (sc-2577, sc-2578) and AP1 (sc-2501, sc2514)
sequences, respectively, were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The probes were labeled with
[gamma-
32P]ATP (3000 Ci/mmol) and purified on Chromaspin
30 columns (Clontech, Palo Alto, CA). Binding assays were
performed as described previously [32].
Genomic DNA preparation and methylated DNA
quantification
HEK cells (1.5 10
6) were seeded into 100 mm plates and
24 hours later, the transfection was performed with 8 microg by
plate of pDest40 plasmid expressing NFRKB, or pDest40 empty
vector, using nanofectine (PAA) according to the supplier’s
instructions. The transfected cells were incubated at 37uC under
5% CO2 for 24 h, then washed twice in 16PBS, resuspended in
500 microl of buffer (50 mM Tris-HCl, 10 mM EDTA, 100
microg/ml DNase free RNaseA, pH8.0) and incubated for 30 min
at 37uC. After RNAse treatment, the samples were incubated with
100 microl of Proteinase K (20 mg/ml) for 8 hours at 37uC. The
DNA samples were extracted twice with phenol equilibrated in
Tris–HCl pH 8 and once with Chloroform/Isoamyl alcool (24:1).
The DNA was ethanol-precipitated and the pellet dissolved in 500
microl sterile water. The concentration of the DNA samples was
measured using a NanoDrop spectrophotometer. The global
methylation level of the DNA samples was measured using the
Inprint
TM Methylated DNA quantification Kit (Sigma, Missouri,
USA), according to the supplier’s protocol. The percentage of
methylated DNA was measured relatively to control DNA
provided in the kit according the supplier’s formula: [(sample
minus blank)/(control minus blank)]6100.
Statistical Analysis
Statistical analysis of the data was performed using PRIZM 4
for Macintosh (Graphpad Software, Inc, USA). Unpaired or
Paired Student t-tests were used. P value of less than 0.05 was
considered significant.
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